CSL

CSL was founded in 1916 and has grown to become a global leader in the biotherapy sector. Headquartered in Melbourne, Australia, the company boasts 27,000 employees working to deliver innovative solutions in healthcare. Under the leadership of CEO Paul Perreault, CSL has established itself as a key player in the development of biotherapeutics and vaccines.

With over a century of expertise, CSL is dedicated to improving the quality of life for patients worldwide through cutting-edge research and development. The company's commitment to healthcare innovation is demonstrated in its extensive portfolio of biotherapies and vaccines, addressing a broad range of medical conditions and needs.

CSL's robust infrastructure and global reach allow it to effectively manage and distribute vital healthcare products, including plasma-derived therapies and vaccines. The company continues to push the boundaries of medical science, leveraging its vast experience and resources to make a significant impact on global health.